Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mycoplasma: a new potential vector for gene therapy?

F Berger1, C Canova, J M Vicat

  • 1INSERM U318, Neurobiologie Préclinique, CHU Michallon, Grenoble, France.

Medical Hypotheses
|August 25, 1999
PubMed
Summary

This study proposes using mycoplasma, the smallest living cell, as a novel vector for gene therapy. This approach aims to express therapeutic genes on target cell surfaces, potentially overcoming gene delivery and expression challenges in eukaryotic cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VOYAGER: an international consortium investigating the role of human papilloma virus and genetics in oral and oropharyngeal cancer risk and survival.

medRxiv : the preprint server for health sciences·2025
Same author

Cross-ancestral GWAS identifies 29 novel variants across Head and Neck Cancer subsites.

medRxiv : the preprint server for health sciences·2024
Same author

Reliability of toxicokinetic modelling for PFAS exposure assessment in contaminated water in northern Italy.

Heliyon·2024
Same author

The risk of epilepsy in children with celiac disease: a population-based cohort study.

European journal of neurology·2020
Same author

Predictors of oropharyngeal cancer survival in Europe.

Oral oncology·2018
Same author

Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: a pooled analysis within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Cell Biology

Background:

  • Gene therapy relies on introducing foreign genetic material into cells, often using viral or synthetic vectors.
  • Current gene therapy methods face challenges with foreign DNA penetration and expression in eukaryotic cells, limiting therapeutic efficiency.

Purpose of the Study:

  • To explore mycoplasma as a novel vector for gene therapy by expressing foreign genes on target cell surfaces.
  • To overcome the limitations of intracellular gene delivery and expression in eukaryotic cells.

Main Methods:

  • Utilizing mycoplasma, the smallest known living cell, as a potential gene therapy vector.
  • Investigating the expression of foreign genes on the surface of target cells via mycoplasma.

Related Experiment Videos

Main Results:

  • Mycoplasma offers potential advantages as a vector, including absence of genetic transfer to host cells, antibiotic sensitivity, and cytadherence.
  • This surface-expression strategy bypasses critical steps of intracellular DNA penetration and expression.

Conclusions:

  • Mycoplasma presents a promising alternative vector for gene therapy, particularly for applications like gene-directed enzyme prodrug therapy for solid tumors.
  • The unique characteristics of mycoplasma could enhance the efficiency and safety of gene therapy approaches.